Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

309
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
309
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

325
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
325
Arboviral Encephalitis01:25

Arboviral Encephalitis

1
Arboviral encephalitis refers to brain inflammation caused by arthropod-borne viruses, particularly those transmitted through mosquito vectors. Among these, West Nile virus (WNV), a member of the Flaviviridae family, is a significant public health concern. WNV is an enveloped, positive-sense, single-stranded RNA virus. Human infection typically begins when an infected mosquito introduces the virus into the dermis during feeding. The primary transmission cycle involves birds as amplifying hosts...
1
Tonsillitis II: Management01:26

Tonsillitis II: Management

519
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
519
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

120
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
120
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.0K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>APOL1</i> Variants, AKI, and Progression to Kidney Failure in People of African Ancestry Living with HIV.

Kidney international reports·2026
Same author

Stigma and depression among heterosexual men and women living with HIV in the UK: Investigating a conceptual framework.

PloS one·2026
Same author

Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study.

Clinical drug investigation·2026
Same author

Development and content validation of the Long COVID/ post-acute sequelae of COVID-19 (PASC) patient-reported outcome (PRO) instrument.

Journal of patient-reported outcomes·2025
Same author

Trends and shortcomings in outpatient management of SARS-CoV-2 infection in high-risk populations: A population-based observational study in France.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2025
Same author

Removal of deferrals for variant Creutzfeldt-Jakob disease risk: Impact on new and previously deferred donors.

Vox sanguinis·2025

Related Experiment Video

Updated: Mar 19, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K

Relapsing CD8+ encephalitis-looking for a solution.

Sharfaraz Salam1, Tatiana Mihalova2, Andrew Ustianowski3

  • 1Department of Neurology, Salford Royal NHS Foundation Trust, Salford, UK Pennine Acute Hospitals NHS Trust, Manchester, UK.

BMJ Case Reports
|June 24, 2016
PubMed
Summary
This summary is machine-generated.

CD8+ encephalitis, an HIV-associated neurological condition, often relapses after steroid treatment. Mycophenolate mofetil offers a promising steroid-sparing option for long-term management of this condition.

More Related Videos

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.9K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Related Experiment Videos

Last Updated: Mar 19, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.3K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.9K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Area of Science:

  • Neuroscience
  • Immunology
  • Infectious Diseases

Background:

  • CD8+ encephalitis (CD8+E) is an emerging HIV-associated neurological syndrome.
  • It presents as steroid-responsive subacute encephalopathy with white matter changes in HIV-infected individuals.
  • Pathophysiology involves autoreactive CD8+ cells attacking HIV-infected CD4+ lymphocytes.

Observation:

  • A case of CD8+E is presented with initial steroid responsiveness.
  • The patient experienced multiple relapses upon steroid withdrawal.
  • This necessitated exploring alternative long-term treatment strategies.

Findings:

  • Mycophenolate mofetil (MMF) was utilized as a steroid-sparing agent.
  • This represents the first reported use of MMF for CD8+E management.
  • Sustained remission was achieved with MMF, allowing steroid dose reduction.

Implications:

  • MMF demonstrates potential as an effective long-term therapy for CD8+E.
  • This approach may prevent relapses and reduce steroid dependence.
  • Further research into MMF for HIV-associated neurological disorders is warranted.